-
Mashup Score: 3Immunology | bioRxiv - 3 day(s) ago
bioRxiv – the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
Source: www.biorxiv.orgCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 0Diagnosing Acute Bacterial vs Viral Rhinosinusitis - 4 day(s) ago
American Family Physician Community Blog, Diagnosing Acute Bacterial vs Viral Rhinosinusitis, written by Lilian White, MD.
Source: www.aafp.orgCategories: General Medicine News, General Journals & SocietTweet-
NEW BLOG: Diagnosing Acute Bacterial vs Viral Rhinosinusitis —Lilian White, MD https://t.co/iCmKbEwt9j #familymedicine #afpjournal #afpblog https://t.co/AKveSRX8Zu
-
-
Mashup Score: 0Video: Etranacogene Dezaparvovec Has Long-Term Efficacy, Can Expand Eligibility for Hemophilia B - 4 day(s) ago
Steven Pipe, MD, explains the long-term efficacy data surrounding etranacogene dezaparvovec in patients with hemophilia B.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
Watch here: https://t.co/rcaLBVpHjO
-
-
Mashup Score: 0Enhancing Outcomes With Immunotherapy Agents for Patients With Non-Muscle Invasive Bladder Cancer - 4 day(s) ago
Panelists at the 2025 ASCO Genitourinary Cancers Symposium discussed challenges and new approaches to treatment.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
Learn more: https://t.co/xLlTsHZ158
-
-
Mashup Score: 1
Background: Cell-free DNA blood tests (cf-bDNA) and next-generation stool tests could change colorectal cancer (CRC) screening. Objective: To estimate the clinical and economic impacts of novel CRC screening tests. Design: Cost-effectiveness analysis using MOSAIC (Model of Screening and Surveillance for Colorectal Cancer). Data sources: Published data. Target Population: Average-risk persons. Time Horizon: Ages 45 to 100 years. Perspective: Health sector. Intervention: Novel versus established CRC screening tests. Outcome Measures: Incidence and mortality of CRC, quality-adjusted life-years (QALYs), costs. Results of Base-Case Analysis: For colonoscopy every 10 years, annual fecal immunochemical test (FIT), and triennial next-generation multitarget stool DNA, FIT-RNA, cf-bDNA (Guardant Shield), or cf-bDNA (Freenome), the relative rates (RRs) and 95% uncertainty intervals (UIs) versus no screening for CRC incidence were 0.21 (0.19 to 0.22), 0.29 (0.27 to 0.31), 0.33 (0.32 to 0.36), 0.32
Source: www.acpjournals.orgCategories: General Medicine News, General Journals & SocietTweet-
New: First-generation novel cell free blood DNA (cf-bDNA) tests have the potential to meaningfully decrease the incidence and mortality of CRC compared with no screening, but substantially less profoundly than colonoscopy or stool tests. https://t.co/V507lZuRA3 @StanfordMed https://t.co/SItkPMeqVD
-
-
Mashup Score: 0Treatment options for preventing autoimmune-mediated congenital heart block: a systematic review - 4 day(s) ago
Objective Complete congenital heart block (CHB) due to anti-Ro/La antibodies in pregnancy can lead to adverse fetal outcomes and neonatal death. National and international guidelines do not recommend specific treatment for women identified with anti-Ro antibodies while pregnant. Design Systematic review of studies of pregnant women with anti-Ro/La antibodies undertaking treatment(s) to prevent CHB. Studies solely focused on treating developing or established CHB were excluded. Main outcome measure CHB incidence. Results Of 1049 articles, 20 studies were eligible, of which 13 were retrospective. Sixteen studies contained usable data comparing various treatments (seven hydroxychloroquine (HCQ), six corticosteroids, two intravenous immunoglobulin (IVIG) and one each on combined HCQ and corticosteroids and plasmapheresis), including 2134 women and 2915 pregnancies. Meta-analysis was not possible due to heterogeneity. HCQ as primary prophylaxis showed protective effect on CHB incidence in f
Source: adc.bmj.comCategories: General Medicine News, General Journals & SocietTweet-
Treatment options for preventing autoimmune-mediated congenital heart block. Most evidence support hydroxychloroquine but high risk of bias and imprecision Systematic review https://t.co/NTuLvUaCXz https://t.co/4VhsRxkYvT
-
-
Mashup Score: 0Use and Discontinuation Rates of Long‐Acting Injectable Antipsychotics Between Race/Ethnicity in Older Adults Using Medicaid Databases - 4 day(s) ago
Objective The primary objective of this study was to assess the prescribing patterns of long acting injectable (LAI) antipsychotics in an older adult population. Secondary objectives were to determi…
Categories: General Medicine News, General Journals & SocietTweet-
The disparities in the prescribing of long acting injectable antipsychotics between Black and White populations. #geriatrics https://t.co/vs0bXuDbmf https://t.co/Q60279pN8X
-
-
Mashup Score: 12Primary Care in Rochester and Kasson - 4 day(s) ago
Water makes up between 50% and 70% of your body weight. It’s essential for every cell, tissue and organ in your body. Water removes waste through urination, perspiration and bowel movements. It’s also a component of the lubrication and cushioning of your joints and helps to regulate your temperature. Environment: You may need more water at higher altitudes or in hot or humid weather. Exercise: If you sweat, you need to replace the water. Sometimes, you may need to include rehydration fluids to add the
Source: communityhealth.mayoclinic.orgCategories: General Medicine News, General Journals & SocietTweet-
Water makes up 50–70% of your body and is essential for your health. It removes waste, cushions joints, and regulates temperature. Your needs depend on factors like activity, weather, and health conditions. Learn more from Dr. Denise Dupras: https://t.co/oFxjaWj5KI https://t.co/h8R0zqJ2hk
-
-
Mashup Score: 1How to use mTOR inhibitors in children - 4 day(s) ago
Paediatricians across many specialities and pharmacists are increasingly being asked to prescribe, or jointly look after, children treated with mammalian target of rapamycin (mTOR) inhibitors (eg, sirolimus and everolimus). There is an expanding list of conditions including tuberous sclerosis and vascular malformations where treatment with mTOR inhibitors may help. This brief practice pointer summarises the practical steps before starting these treatments, what potential side effects to discuss with families and what monitoring arrangements should be put in place.
Source: ep.bmj.comCategories: General Medicine News, General Journals & SocietTweet-
Medicines update Many specialities increasingly using mammalian target of rapamycin (mTOR) inhibitors (eg, sirolimus and everolimus) in children. Practical guide https://t.co/uRTBCGCRqW https://t.co/lnIwxdqWJs
-
-
Mashup Score: 0
Data from the phase 2 CABRAMET trial suggests the potential of cabozantinib for treatment of brain metastases from renal cell carcinoma (RCC).
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
Learn more: https://t.co/pBV2k9nMjm
-
New papers posted on August 14, 2024: 1 in immunology: https://t.co/I7DRZezf0S 8 in microbiology: https://t.co/uVMmwwTmD4 1 in molecular biology: https://t.co/CnFa1ZO18j 2 in neuroscience: https://t.co/ES0ayAHKiZ 1 in synthetic biology: https://t.co/NvtWK7Xiza